Cellphire -Pipeline of Cellular Therapies

Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes, is an activated platelet-based hemostatic. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. Thrombosomes has also been given orphan drug designation for the treatment of Acute Radiation Sickness by the U.S. Food and Drug Administration.